The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin’s lymphoma tumor growth by promoting apoptosis and autophagy

BACKGROUND: Aggressive B-cell non-Hodgkin’s lymphoma (B-NHL) patients often develop drug resistance and tumor recurrence after conventional immunochemotherapy, for which new treatments are needed. METHODS: We investigated the antitumor effects of CBL0137. In vitro, cell proliferation was assessed by...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Yan, Du, Yuxin, Li, Kening, Ma, Xiao, Wang, Juan, Du, Tongde, Ma, Yuxin, Teng, Yue, Tang, Weiyan, Ma, Rong, Wu, Jianqiu, Wu, Jianzhong, Feng, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869543/
https://www.ncbi.nlm.nih.gov/pubmed/36691066
http://dx.doi.org/10.1186/s12964-022-01031-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869543/
https://www.ncbi.nlm.nih.gov/pubmed/36691066
http://dx.doi.org/10.1186/s12964-022-01031-x

Ejemplares similares